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Background: Fentanyl buccal soluble ﬁlm (FBSF) has been developed as a treatment of breakthrough pain in opioid-
tolerant patients with cancer. The objective of this study was to evaluate the efﬁcacy of FBSF at doses of 200–1200 lg
in the management of breakthrough pain in patients with cancer receiving ongoing opioid therapy.
Patients and methods: This was a multicenter, randomized, double-blind, placebo-controlled, multiple-crossover
study that included opioid-tolerant adult patients with chronic cancer pain who experienced one to four daily episodes
of breakthrough pain. The primary efﬁcacy assessment was the sum of pain intensity differences at 30 min (SPID30)
postdose.
Results: The intent-to-treat population consisted of 80 patients with ‡1 post-baseline efﬁcacy assessment. The least-
squares mean (LSM 6 SEM) of the SPID30 was signiﬁcantly greater for FBSF-treated episodes of breakthrough pain
than for placebo-treated episodes (47.9 6 3.9 versus 38.1 6 4.3; P = 0.004). There was statistical separation from
placebo starting at 15 min up through 60 min (last time point assessed). There were no unexpected adverse events
(AEs) or clinically signiﬁcant safety ﬁndings.
Conclusions: FBSF is an effective option for control of breakthrough pain in patients receiving ongoing opioid
therapy. In this study, FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs.
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introduction
Pain related to chronic conditions such as cancer is often
characterized by two components. The ﬁrst component is
persistent pain, and the recommended treatment is long-acting
opioid products. The second component is often referred to as
‘breakthrough pain’. Breakthrough pain is deﬁned as the
‘transient exacerbation of pain occurring in a patient with
otherwisecontrolledpersistentpain’[1].Aninternationalsurvey
of 58 clinicians in 24 countries evaluated a total of 1095 patients
with cancer pain of an intensity that needed treatment with
opioid analgesics to determine the prevalence of breakthrough
pain [2]. Breakthrough pain was reported in 64.8% of these
patients and was associated with higher pain scores and
functional impairment on the Brief Pain Inventory [2].
Breakthrough pain episodes have been routinely treated with
oral short-acting opioids, including hydrocodone,
hydromorphone, morphine, and oxycodone [3]. Although
these treatments are widely used, the variable absorption of oral
opioids from the gastrointestinal tract may result in delayed
pain relief (PR) (up to 40 min after administration) [4] and
may lead to variability in the therapeutic effect. In a Pan-
European survey [5], it was reported that 63% of patients with
cancer receiving prescription analgesics reported breakthrough
pain or inadequate PR. Of those patients, 58% reported that
they had inadequate PR at all times.
As an alternative to oral administration, transdermal and
transmucosal routes of administration have been used to
deliver pain medication. With transmucosal delivery,
absorption through the oral mucosa from either the buccal
cavity or sublingually is more rapid than oral absorption [6].
Other beneﬁts of oral transmucosal delivery include
minimization of ﬁrst-pass metabolism and better tolerance for
patients with dysphagia (especially dysphagia due to conditions
such as head and neck cancer [7]) or those who have
experienced nausea or vomiting [8].
Fentanyl is a potent opioid analgesic that is well absorbed via
the oral mucosa. Currently, there are various formulations
approved by regulatory authorities. Oral transmucosal fentanyl
citrate (OTFC) (United States and Europe: Actiq
 ; Cephalon,
Inc., Frazer, PA) is a buccal formulation composed of a fentanyl
lozenge on a stick. This formulation requires patient effort for
administration, and absorption is dependent on the individual
application technique. A second buccal formulation, the
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 ; Europe:
Effentora
 ; Cephalon), has been approved in the United
States and Europe. This formulation utilizes an effervescence
reaction that is postulated to be responsible of an enhanced
fentanyl absorption through the buccal mucosa above that
achievable with OTFC. More recently, a sublingual tablet
formulation of fentanyl (Europe: Abstral
 ;O r e x o ,I n c . ,
Uppsala, Sweden) that uses mucoadhesives to hold the
fentanyl in contact with the mucosa membrane has been
marketed in Europe.
The most recent product to be approved by the United States
Food and Drug Administration, a fentanyl buccal soluble ﬁlm
(FBSF) (United States: Onsolis
 ; Meda Pharmaceuticals Inc.,
Somerset, NJ; Europe: Breakyl
  and Buquel
 ), has been
developed to control breakthrough pain in patients with cancer
and is intended for direct application to the oral mucosa. FBSF
utilizes BioErodible MucoAdhesive (BEMA ; BioDelivery
Sciences, Inc., Raleigh, NC) technology to deliver fentanyl
across the buccal mucosa. The technology uses a dual-layer
polymer ﬁlm consisting of a mucoadhesive layer that contains
the active drug and an inactive layer that helps to prevent
diffusion of drug into the oral cavity. The mucoadhesive layer
adheres to a moist mucosal membrane in seconds. FBSF starts
to dissolve in minutes and is completely dissolved within 15–30
min after application without patient effort, requiring only
a minimal amount of saliva to dissolve once adhered. Previous
studies have shown that when delivered by this system, the
proportion of the fentanyl dose that undergoes transmucosal
absorption is 50% and the absolute bioavailability is 71%.
The direct relationship between the surface area of the dose unit
andthedose of fentanylcombined withthe mucosacontact time
results in consistent plasma concentrations when equivalent
doses are delivered by single or multiple dosage units [9].
The objective of the present study was to evaluate the efﬁcacy
and safety of FBSF at doses ranging from 200 to 1200 lg in the
management of breakthrough pain in patients with cancer
receiving around the clock opioid therapy.
methods
trial design
This was a multicenter, randomized, double-blind, placebo-controlled,
crossover study comparing FBSF with placebo for the treatment of
breakthrough pain in patients with cancer receiving a stable opioid regimen
for persistent pain. Breakthrough pain was deﬁned as moderate-to-severe
pain that occurred at a speciﬁc site for a transitory period against
a background of persistent pain controlled by the around the clock opioid
regimen. The study consisted of a screening period of up to 1 week, an
open-label titration period of up to 2 weeks, a double-blind period of up to
2 weeks, and a 1-day follow-up. In the titration period, patients were issued
an electronic diary and a dose-titration kit containing ﬁve doses of each of
the ﬁve dose strengths (200, 400, 600, 800, and 1200 lg) of FBSF. Each
subject started with the 200-lg dose and increased their dose in a stepwise
manner until adequate PR was achieved. Patients unable to identify a dose
that produced satisfactory PR and those not completing the titration within
2 weeks were discontinued from the study. Patients who identiﬁed a dose
that produced satisfactory PR for at least two target breakthrough pain
episodes were eligible to enter the double-blind crossover period. During
the double-blind period, patients received nine doses of study medication:
six contained fentanyl at the effective dose for that patient and three were
placebo. The order in which the patient received FBSF or placebo was
determined by a computer-generated randomization code. At no time did
patients receive two placebos in a row. Subjects were allowed to use their
usual rescue medication if adequate PR was not realized within 30 min.
Patients were not allowed to take another study dose for 4 h after their last
dose of study drug. Any subsequent dose of study medication was for the
emergence of a new target breakthrough pain episode and not an
unresolved previously treated episode. Subjects remained in the double-
blind period of the study until all nine doses of study medication were taken
or until 14 days after entry into the double-blind period of the study.
The study protocol was approved by the institutional review board of
each participating center. The study was conducted in accord with
provisions of the World Medical Association Declaration of Helsinki and its
most recent amendment concerning medical research in humans (2004)
and conformed to all local laws and regulations (whichever provided the
greater protection to individual patients). Documentation and procedures
complied with the International Conference on Harmonisation Guideline
E6 (R1) and the USA Code of Federal Regulations (Title 21, Part 50). All
patients read and signed an approved informed consent form before
enrollment procedures commenced.
patients
inclusion criteria. Patients eligible for the study were men or nonpregnant
nonlactating women aged 18 years or older with pain associated with cancer
or cancer treatment that required opioid therapy. The opioid dosage
regimen must have been stable at the time of enrollment and was required
to be equivalent to 60–1000 mg/day of oral morphine or 50–300 lg/h of
transdermal fentanyl. Eligible patients were experiencing one to four
episodes of breakthrough pain daily that required opioids for pain control,
for which opioids provided at least partial relief.
exclusion criteria. Patients with more than four episodes of breakthrough
pain per day and those with rapidly escalating pain that the investigator
believed may require an increase in the dosage of the background opioid
were not eligible for the study, as were those who had received strontium 89
during the previous 6 months and those receiving any other therapy that
could alter pain or the patient’s response to pain medication.
drug administration
Eligible patients received instruction on handling and application of FBSF
dose units. Patients were instructed to apply the mucoadhesive side of the
thin ﬁlm unit (about half the thickness of a business card or roughly
equivalent to 2.5 dollar bills) to a moistened (saliva or water) buccal
mucosa and to hold it in place for 5 s. The FBSF dose unit adheres to the
mucosal membrane, becoming pliable within a minute, and then
completely dissolves over a period of 15–30 min.
Patients were allowed to use their usual rescue medication 30 min after
self-administration of a study dose for episodes of pain that were not
adequately controlled by the study medication.
assessments
efﬁcacy. Pain intensity (PI) and PR were assessed at 5, 10, 15, 30, 45, and 60
min after each double-blind study dose. PI was measured on an 11-point
scale (0 = no pain and 10 = worst pain) and the PI difference calculated as
the baseline PI minus the assessment point PI. PR was measured on a
5-point scale (0 = no relief to 4 = complete relief). PI differences (PID =
baseline PI minus PI at assessment point) were calculated, and the weighted
sum over the ﬁrst 30 min postdose (SPID30) was deﬁned as the primary
outcome measure. Secondary outcome measures included PID and PR
calculated at various time points throughout the study period and the sums
of PID (SPID) were calculated over various intervals. Global satisfaction
was assessed on a 5-point scale (poor, fair, good, very good, and excellent)
at the time of rescue or 60 min after study dose.
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therapeutic decisions, and drug history, was assessed at the screening visit.
A complete physical examination was carried out and vital signs measured
at the screening and follow-up visits. Adverse events (AEs) were reported
and assessed throughout the study with an electronic diary. Concomitant
medications were monitored throughout the study.
statistical analyses
Efﬁcacy analyses were conducted using the intent-to-treat (ITT)
population, deﬁned as all patients who entered the double-blind phase of
the trial, who took at least one dose of study medication and had at least
one pain assessment within the 30-min postdose period. The safety
population was deﬁned as all patients who received at least one dose of
study medication in the dose-titration and double-blind treatment phases
of the study.
All statistical analyses were carried out by using a two-sided hypothesis
test with a type I error (alpha) of 0.05 (i.e., a 5% level of statistical
signiﬁcance). Efﬁcacy data are presented as least-squares means (LSM) and
standard errors. The primary efﬁcacy parameter, SPID30, was analyzed
using a mixed model of repeated measures with ﬁxed effects for treatment,
pooled site, and a random effect for subjects. The secondary efﬁcacy
parameters were analyzed using the one-sample Wilcoxon signed rank test.
results
patient disposition and demographics
The study was conducted at 30 clinical sites in the United States
between 24 February 2006 and 14 March 2007. A total of 152
patients were screened and enrolled in the study, and 151
patients received at least one dose of study medication and were
included in the safety population (Figure 1).
Of the 151 patients enrolled in the titration phase, 69 (45.7%)
discontinued the study. The reasons for withdrawal were the
following:17(11.3%)forAEs,15(9.9%)becauseofdifﬁcultiesor
noncompliance with the electronic diary, 14 (9.3%) withdrew
consent without explanation, 8 (5.3%) were withdrawn for
protocol violations, 7 (4.6%) because they had less than a single
episode of breakthrough pain a day, 5 (3.3%) for lack of efﬁcacy,
and 3 (2.0%) patients for administrative reasons.
Figure 1. Flow of patients through the study. ITT, intent-to-treat; PP, per protocol.
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double-blind phase of the study for the following reasons: 4
(4.9%) withdrew consent, 3 (3.7%) because of AEs, 2 (2.4%)
for noncompliance with the electronic diary, 2 (2.4%) for not
consistently treating one episode of pain per day, and 1 (1.2%)
for lack of efﬁcacy.
A total of 70 patients in the safety population did not receive
any study drug in the double-blind treatment phase of the
study, and 1 patient did not have a pain assessment within 30
min of taking a dose of study drug during the double-blind
phase of the study; thus, the ITT population consisted of 80
patients.
A summary of the demographic characteristics of patients
included in the safety and efﬁcacy populations is provided in
Table 1. There were no important differences in the baseline
characteristics of the safety and ITT populations. Breast cancer
(23%), lung cancer (17%), colorectal cancer (11%),
gastroesophageal cancer (7%), pancreatic cancer (6%), and
head and neck cancer (5%) were the most common cancer
types in the safety population. Overall, patients had suffered
from the current primary cancer for a mean period of 3.2 years
with a median of 1.6 years and a range of <1t o>30 years. More
than half of the patients (55.6%) had received chemotherapy
and one-quarter (25.2%) had received radiation therapy in the
last 6 months before study entry.
For approximately half of the patients in the safety
population, the pain pathophysiology for both persistent pain
and target breakthrough pain was somatic and/or visceral.
Forty-nine patients (32.5%) also experienced neuropathic pain.
For most patients in the safety population, the pain syndrome
for persistent and target breakthrough pain was typically related
to direct tumor involvement (84.8% and 86.1% of patients,
respectively) or due to somatic/visceral lesions (83.4% and
84.8% of patients, respectively).
The most common stable opioid regimen was transdermal
fentanyl for persistent pain, taken by 46.4% of patients, and
hydrocodone for target breakthrough pain, taken by 42.4% of
patients. Long-acting oral morphine was used in 23.8% of
patients for persistent pain and short-acting oral morphine was
used in 26.5% of patients for target breakthrough pain. For
nearly all patients [149 of 151 (98.7%)] in the safety
population, there were minimal opioid side-effects from the
current daily opioid dose.
dosing
Patients received a mean of 9.3 doses of FBSF during the dose-
titration phase. During the double-blind treatment phase,
patients received a mean of 5.5 doses of FBSF and 2.8 doses of
placebo. Patients received a total of 14.0 doses of FBSF over the
course of the study.
In the double-blind portion of the study, the number of
individuals dosed at 200, 400, 600, 800, or 1200 lg was 4
(4.9%), 15 (18.5%), 23 (28.4%), 19 (23.5%), and 20 (24.7%),
respectively. The effective dose for most patients was ‡400 lg.
The mean duration of exposure to the study drug was 6.6 days
in the titration period, 5.9 days in the double-blind period, and
10.1 days in the entire study period. The minimum period of
exposure was 1 day and the maximum was 27 days.
efﬁcacy
At baseline, the mean PI score was 6.9 and the median PI score
was 7.0 for both FBSF- and placebo-treated episodes. A total of
394 FBSF episodes and 197 placebo episodes were included in
the ITT analysis of the primary efﬁcacy end point.
The LSM 6 SEM of the SPID30, the primary efﬁcacy variable,
was signiﬁcantly greater for FBSF-treated episodes of
breakthrough pain than for placebo-treated episodes (47.9 6 3.9
versus 38.1 6 4.3; P = 0.004). The SPID values for FBSF-treated
episodes were consistently greater compared with placebo-
treated episodes at all postdose time points. There was
statistically signiﬁcant separation from placebo starting at 15
min postdose (P < 0.05) through 60 min postdose [the last time
point assessed (P < 0.001)] (Figure 2).
Similarly, PID (Figure 3) values for FBSF-treated episodes
were consistently greater compared with placebo-treated
episodes at 10 min postdose and all time points beyond, with
the difference reaching statistical signiﬁcance at 30 min. The PR
values were statistically signiﬁcant from placebo starting at 30
min postdose (P < 0.01) and continuing until the last
assessment (P < 0.01).
The percentage of episodes with a 33% or 50% decrease in
pain was also signiﬁcantly greater with FBSF than with placebo
(Table 2). Overall satisfaction with the study drug was
signiﬁcantly greater with FBSF than with placebo (mean score
2.0 versus 1.5, respectively; P < 0.001). Moreover, more patients
rated their overall satisfaction with FBSF as good, very good, or
excellent compared with placebo (Figure 4). Conversely, fewer
patients rated their overall satisfaction with FBSF as poor or fair
Table 1. Demographic data
Demographic Safety population
(n = 151)
Efﬁcacy (ITT)
population
(n = 80)
Gender, n (%)
Male 66 (44) 36 (45)
Female 85 (56) 44 (55)
Mean (SD) age in years 57.1 (12.2) 56.8 (13.0)
Age in years, n (%)
<65 104 (69) 55 (69)
‡65 47 (31) 25 (31)
Race, n (%)
White 131 (86.8) 72 (90.0)
Black 12 (7.9) 6 (7.5)
Asian 1 (0.7) 0
Other 7 (4.6) 2 (2.5)
Mean (SD) height, cm 168.7 (9.8) 169.2 (9.3)
Mean (SD) weight, kg 73.0 (19.1) 74.5 (17.8)
Mean (SD) duration since
diagnosis in years
3.2 (4.5) 3.7 (5.2)
Median (range) duration
since diagnosis in years
1.6 (0.0–30.3) 2.17 (0.0–30.3)
Cancer treatment in previous 6 months, n (%)
Chemotherapy 84 (56) 43 (54)
Radiation 38 (25) 15 (19)
ITT, intent-to-treat; SD, standard deviation.
Annals of Oncology original article
Volume 21|No. 6|June 2010 doi:10.1093/annonc/mdp541 | 1311compared with placebo (Figure 4). The mean (6 SEM) number
of episodes when rescue medication was used was signiﬁcantly
lower after treatment with FBSF than with placebo (30.0% 6
3.5% versus 44.6% 6 4.4%; P = 0.002).
safety
Twenty-three patients (15.2%) experienced 29 serious AEs.
None of these serious AEs were considered to be related to the
study drug. Respiratory depression was not reported by any
patient enrolled in the study. There were four deaths during the
study, none of which were considered to be study drug related.
Twenty-one patients (13.9%) discontinued study drug
administration because of treatment-emergent AEs, including 9
serious AEs and 12 nonserious AEs. Nausea and vomiting were
the most common AEs leading to permanent study drug
discontinuation (3.3% of patients, respectively).
Treatment-emergent AEs were reported by 75 patients
(49.7% of 151 patients) during the titration period and 34
patients (42% of 81 patients) during the double-blind period.
The most common treatment-emergent AEs were typical of
opioid administration and occurred with similar frequency
during the titration and double-blind phases. Treatment-
emergent AEs reported during the titration phase included
nausea (9.3%), vomiting (9.3%), somnolence (6.0%), dizziness
(4.6%), and headache (4.0%). Treatment-emergent AEs
reported during the double-blind phase included nausea
(9.9%), vomiting (9.9%), and headache (1.2%).
Most AEs [213 of 273 (78.0%)] in 47 patients were not
considered to be drug related. A total of 56 drug-related AEs
were reported by 37 of the 151 patients (24.5%) included in the
safety population. One patient had four AEs, and it could not
be determined whether those events were drug related. The
most common drug-related AEs were gastrointestinal disorders
and central nervous system disorders (Table 3). These AEs
included somnolence (6.0%), nausea (5.3%), dizziness (4.6%),
and vomiting (4.0%). These AEs are commonly associated with
opioid therapy.
Only ﬁve patients (3.3%) reported oral AEs (n = 2, mild
mucosal inﬂammation; n = 3, oral candidiasis) and all these
events were considered to be unrelated to study treatment in
the opinion of the investigator. No oral ulcerations, pain, or
edema associated with the study drug were observed in the
study population.
discussion
The results of this study demonstrate that FBSF is more
effective than placebo for the management of breakthrough
pain in opioid-tolerant patients with cancer. The SPID values
were signiﬁcantly greater for FBSF-treated episodes than for
placebo-treated episodes beginning 15 min after drug
administration and continuing through 60 min. Similarly, pain
scores for FBSF-treated episodes were signiﬁcantly lower than
for placebo-treated episodes at 30, 45, and 60 min after dosing.
At 30 min postdose, reductions in PI of at least 33% and of at
least 50% were obtained in signiﬁcantly more FBSF-treated
episodes than in placebo-treated episodes (P = 0.009 and
P = 0.002, respectively). Patients gave favorable ratings to
a numerically higher proportion of pain episodes treated with
FBSF than with placebo (P < 0.001).
Of 152 patients on stable opioid therapy for cancer pain who
entered the dose-titration phase of the study, 53.9% entered the
double-blind phase. The most common reasons for dropout
from the titration phase were noncompliance with study
procedures, including use of the electronic diary card. Of the
subjects who began titration, 3.3% did not continue in the
study because they were not able to ﬁnd an effective dose of
FBSF for breakthrough pain.
It has been reported that more than half of patients receiving
prescription medicine for cancer pain experience inadequate
PR or breakthrough pain [5]. This ﬁnding indicates that
additional pharmacotherapeutics that are well tolerated and
have rapid onsets of action are needed to treat this patient
population. Transmucosal fentanyl preparations are approved
in the United States for the treatment of breakthrough pain in
patients with cancer, including OTFC, FBT [10, 11], and FBSF.
OTFC has been shown to provide more effective PR than
immediate-release morphine in a study population similar to
Figure 2. Mean sum of pain intensity difference (SPID) scores over
time.*P < 0.05; **P < 0.01; ***P < 0.001. SEM, standard error of the mean.
Figure 3. Mean pain intensity difference over time.*P < 0.05; **P < 0.01;
***P < 0.001. SEM, standard error of the mean.
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shown to produce plasma fentanyl concentrations earlier and
greater than an equal dose of OTFC in normal volunteers [13].
FBSF was safe and well tolerated by patients enrolled in this
study. The AEs reported during the study were typical of those
associated with opioid analgesics. No patients experienced
respiratory depression and none of the serious AEs were
considered to be study drug related. No drug-related oral AEs
were reported in this study. The dropout rate observed in this
study due to treatment-emergent AEs was 13.9%. Five patients
(3.3%) withdrew due to lack of efﬁcacy during the open-label
titration phase and one patient (1.2%) withdrew due to lack of
efﬁcacy during the double-blind phase. No patients dropped
out due to site administration AEs.
There are several important clinical implications of the
results reported here. There was a statistically signiﬁcant
decrease in SPID compared with placebo as early as 15 min
after drug administration and continuing through 60 min; thus,
FBSF provides rapid effective relief of breakthrough pain in
patients with cancer. FBSF is safe and well tolerated, with no
oral AEs attributed to the drug. There was a low rate of failure
to control pain in these patients. These ﬁndings are of
particular importance considering the special needs of patients
with cancer who may have trouble swallowing, mucosal
problems (mucositis and thrush), or xerostomia.
One interesting aspect of this study was the unusual placebo
response to the ﬁlm. When the results of the study of FBT by
Portenoy et al. [14] are compared with that in the FBSF study,
it is apparent that the response to placebo was consistently
higher in our trial [e.g., placebo PID at 30 min was 36% higher
in this trial than in the buccal tablet trial (1.9 versus 1.4)]. The
reason for the higher placebo response in a similar patient
population is not readily apparent, but there are several
possibilities. Placebo rates tend to be high in pain studies, with
estimates ranging from 15% to 53% [15], and expectation plays
an important role in their magnitude [16–18]. In this sense, the
innovative and unconventional technology of FBSF might have
generated high expectations in both investigators and patients
and contributed to the high placebo response rate. Speciﬁcally,
the bilayer delivery technology used for FBSF incorporates the
fentanyl into the layer that adheres to the buccal mucosa and
isolates the fentanyl from the saliva by the inactive layer that
contains the taste masking agents. It is believed that this design
not only optimizes fentanyl delivery across the buccal mucosa
but also minimizes fentanyl contact with the taste buds, making
it very difﬁcult for most patients to distinguish between active
and placebo treatments based on taste.
This study has the limitation of being done in an enriched
population of patients, those who responded during the open-
label titration phase of the study. Thus, our results may not
apply to all patients seen in clinical practice. However, there
was a low rate of failure to control pain in patients who
continued into the double-blind phase of the study.
Figure 4. Overall satisfaction with study drug.
Table 3. Incidence of drug-related adverse events that occurred in two
or more patients (n = 151)
Adverse event Incidence, n (%)
Somnolence 9 (6.0)
Nausea 8 (5.3)
Dizziness 7 (4.6)
Vomiting 6 (4.0)
Headache 4 (2.6)
Constipation 3 (2.0)
Dry mouth 2 (1.3)
Dysgeusia 2 (1.3)
Pruritus 2 (1.3)
Confusional state 2 (1.3)
Table 2. Percentage of episodes with decreases in pain scores (mean 6 SEM)
Parameter Treatment Time post-administration
(min)
15 30 45 60
Percentage of episodes with
‡33% reduction in pain
scores
FBSF 26.4 (3.55) 47.3 (4.05) 57.5 (3.93) 64.3 (3.72)
Placebo 21.3 (3.66) 38.2 (4.45) 46.5 (4.50) 48.2 (4.51)
P value 0.100 0.009 0.004 <0.001
Percentage of episodes with
‡50% reduction in pain
scores
FBSF 14.9 (2.81) 32.8 (3.78) 41.1 (4.11) 46.3 (4.17)
Placebo 14.7 (3.35) 24.1 (3.87) 30.5 (4.10) 34.0 (4.30)
P value 0.963 0.002 0.008 0.005
FBSF, fentanyl buccal soluble ﬁlm.
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breakthrough pain in patients receiving ongoing opioid
therapy. In this study, FBSF was well tolerated and there were
no reports of treatment-related AEs.
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